Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Warfarin for Left Ventricular Thrombus (RIVAWAR)
NCT04970576Phase 4Completed
- Sponsor
- National Institute of Cardiovascular Diseases
- Start
- Jun 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rivaroxaban in left ventricular thrombus (LVT) (2 arms), sponsored by National Institute of Cardiovascular Diseases. Primary endpoint: Left ventricular thrombus resolution at 12 weeks. Started Jun 2021; status: completed.
02
Drugs
rivaroxaban
03
Conditions
left ventricular thrombus (LVT)
Beyond the preview
Go deeper on NCT04970576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04970576.